Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

NCT03099382 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

457

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Carcinoma

Interventions

BIOLOGICAL: camrelizumab
DRUG: Docetaxel
DRUG: Irinotecan

Sponsor

Jiangsu HengRui Medicine Co., Ltd.